Abstract
Background: Leukotriene receptor antagonist including montelukast, may have neuropsychiatric adverse effects, but findings have been conflicting, also in paediatric patients.
Objective: To assess if montelukast exposure in children with asthma is associated with onset of neuropsychiatric adverse events using data from the Danish nationwide health registers.
Methods: Children aged 5-17 years with either ≥1 prescription redemption of inhaled corticosteroids or montelukast, or with at least one hospital contact with asthma between January 1, 2010 and December 31, 2018 were included.
Outcomes were: use of neuropsychiatric medicine (Outcome 1), and hospital contacts with a neuropsychiatric diagnosis (Outcome 2). All outcomes were assessed at 90 days of exposure to montelukast. Children who used neuropsychiatric medicine at baseline were excluded in assessment of Outcome 1.
Results: We identified 193,994 children with asthma. No association was found between initiation of montelukast and Outcome 1 or Outcome 2, respectively (HR (95% CI) = 1.08 (0.97-1.18), p=0.18, and HR (95% CI) = 0.92 (0.77-1.10), p=0.36).
Conclusion: Initiating montelukast in children with asthma was not associated with the onset of neuropsychiatric events.
Objective: To assess if montelukast exposure in children with asthma is associated with onset of neuropsychiatric adverse events using data from the Danish nationwide health registers.
Methods: Children aged 5-17 years with either ≥1 prescription redemption of inhaled corticosteroids or montelukast, or with at least one hospital contact with asthma between January 1, 2010 and December 31, 2018 were included.
Outcomes were: use of neuropsychiatric medicine (Outcome 1), and hospital contacts with a neuropsychiatric diagnosis (Outcome 2). All outcomes were assessed at 90 days of exposure to montelukast. Children who used neuropsychiatric medicine at baseline were excluded in assessment of Outcome 1.
Results: We identified 193,994 children with asthma. No association was found between initiation of montelukast and Outcome 1 or Outcome 2, respectively (HR (95% CI) = 1.08 (0.97-1.18), p=0.18, and HR (95% CI) = 0.92 (0.77-1.10), p=0.36).
Conclusion: Initiating montelukast in children with asthma was not associated with the onset of neuropsychiatric events.
Original language | English |
---|---|
Journal | The European Respiratory Journal |
Volume | 62 |
Issue number | Suppl 67 |
Pages (from-to) | PA5363 |
Number of pages | 1 |
ISSN | 0903-1936 |
DOIs | |
Publication status | Published - 2023 |